Supplementary Figures S1-S5 from Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

Supplementary Figures S1-S5. Figure S1: Kinase selectivity of alectinib, vandetanib, cabozantinib, sorafenib, sunitinib, and ponatinib against several kinases including RET. Figure S2: Effect of crizotinib or LDK378 against Ba/F3 cells expressing KIF5B-RET. Figure S3: Effects of alectinib on the expression levels of phospho-ERK, ERK, and BIM in Ba/F3 cells expressing KIF5B-RET. Figure S4: Structures of RET, RET V804L, and V804M with alectinib and vandetanib. Figure S5: X-ray structure of crizotinib with ROS1 and 3D models of alectinib and LDK378 on ROS1.